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Abstract
Proteins with long, pathogenic polyglutamine (polyQ) sequences have an enhanced propensity to spontaneously misfold
and self-assemble into insoluble protein aggregates. Here, we have identified 21 human proteins that influence polyQ-
induced ataxin-1 misfolding and proteotoxicity in cell model systems. By analyzing the protein sequences of these
modifiers, we discovered a recurrent presence of coiled-coil (CC) domains in ataxin-1 toxicity enhancers, while such domains
were not present in suppressors. This suggests that CC domains contribute to the aggregation- and toxicity-promoting
effects of modifiers in mammalian cells. We found that the ataxin-1–interacting protein MED15, computationally predicted
to possess an N-terminal CC domain, enhances spontaneous ataxin-1 aggregation in cell-based assays, while no such effect
was observed with the truncated protein MED15DCC, lacking such a domain. Studies with recombinant proteins confirmed
these results and demonstrated that the N-terminal CC domain of MED15 (MED15CC) per se is sufficient to promote
spontaneous ataxin-1 aggregation in vitro. Moreover, we observed that a hybrid Pum1 protein harboring the MED15CC
domain promotes ataxin-1 aggregation in cell model systems. In strong contrast, wild-type Pum1 lacking a CC domain did
not stimulate ataxin-1 polymerization. These results suggest that proteins with CC domains are potent enhancers of polyQ-
mediated protein misfolding and aggregation in vitro and in vivo.
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Introduction
Accumulation of misfolded proteins with pathogenic polygluta-
mine (polyQ) tracts in insoluble aggregates is a hallmark of late-
onset neurodegenerative diseases, including Huntington’s disease
(HD) and spinocerebellar ataxias (SCAs) [1,2]. Misfolded proteins
in neurons are often deposited in cytoplasmic or nuclear inclusion
bodies that can be readily detected with immunohistological
methods in brains of patients and transgenic mice [3]. Experi-
mental evidence was presented that aggregation of disease proteins
in model organisms is associated with neuronal dysfunction and
toxicity [4], suggesting that this process is causally linked to
pathogenesis. However, data indicating that formation of inclusion
bodies may be protective for mammalian cells have also been
reported [3]. Insoluble protein aggregates are less mobile than
soluble polyQ proteins and therefore have a diminished ability to
associate with essential cellular factors [5,6]. Thus, the question
whether polyQ-mediated protein aggregation is deleterious or
protective for cells still remains unanswered.
Various experimental studies indicate that pathogenic polyQ
tracts with ,40 or more glutamine residues drive spontaneous
misfolding and aggregation of disease proteins such as huntingtin
(HTT), ataxin-1 (ATXN1) and ataxin-3 (ATXN3) [7,8]. The
structural basis of polyQ-mediated protein aggregation is believed
to be the formation of ‘‘polar zippers’’, in which b-sheets are
stabilized by hydrogen bonds between polar amino acids [9].
Once monomers of polyQ-proteins are joined together by
hydrogen bonds they efficiently self-assemble into large, ordered
protein aggregates with a characteristic fibrillar cross b-sheet
structure [7,8].
The kinetics of spontaneous polyQ-mediated protein assembly
is influenced by the concentration, the amino acid composition
and the size of a disease protein. For instance, full-length HTT,
with a pathogenic polyQ tract ($40 glutamines), does not
spontaneously self-assemble into insoluble protein aggregates in
mammalian cells [10]. In contrast, short N-terminal HTT
fragments with pathogenic polyQ sequences form aggregates very
efficiently in various disease model systems [11,12]. Similar results
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were obtained with other polyQ proteins such as ATXN1 or
ATXN3 [13], suggesting that proteolytic cleavage of disease
proteins in patient brains is a prerequisite for polyQ-mediated
protein aggregation. This hypothesis was confirmed recently in a
study that demonstrated ATXN3 processing to be critical for
spontaneous protein aggregation in iPSC-derived neurons from
SCA3 patients [14]. Also, experimental evidence has been
presented that specific domains in disease proteins influence their
propensity to spontaneously form insoluble aggregates. In
ATXN1, e.g., a C-terminal self-association region (SAR) crucial
for spontaneous polyQ-mediated protein aggregation was identi-
fied [15]. Deleting this region reduced the ability of pathogenic
ATXN1 to form inclusion bodies in disease model systems;
however, proteotoxicity and neurodegeneration were still detect-
able [16], supporting the view that neurotoxicity is caused by
soluble proteins with expanded polyQ tracts rather than by
insoluble protein aggregates.
In the last decade a number of proteins have been reported to
influence misfolding and aggregation of polyQ-containing disease
proteins in model systems like yeast, worm or flies [17–26]. These
modulators are functionally involved in various cellular processes,
including RNA metabolism, protein synthesis, protein folding and
protein degradation. However, the molecular mechanisms by
which such modulators control the toxicity of polyQ-containing
disease proteins in model organisms are not well understood. Also,
it remains to be investigated whether their human homologues
show similar effects in mammalian cells and are relevant for
disease pathogenesis.
In this study, we searched for human proteins that influence
toxicity and aggregation of pathogenic ATXN1 in cell model
systems. Using literature information on lower model organisms
we first predicted ,200 potential human modifiers. These were
then systematically tested in cell-based assays. Using this approach,
we identified 21 human proteins, most of which significantly
influenced both toxicity and aggregation of pathogenic ATXN1 in
mammalian cells. In computational studies we predicted that
many ATXN1 toxicity enhancers contain putative coiled-coil (CC)
domains. Strikingly, no such domains were predicted for toxicity
suppressors, suggesting that CC regions in modifiers are critical for
their aggregation and toxicity promoting effects on polyQ disease
proteins. We then investigated in more detail whether the ATXN1
interacting proteins MED15 and Pum1 directly influence polyQ-
mediated ATXN1 aggregation in cell-free assays. MED15
contains a relatively large computationally predicted N-terminal
CC domain, while such a domain was not predicted for Pum1. We
found that MED15 but not Pum1 efficiently promotes spontane-
ous ATXN1 aggregation in vitro, suggesting that the N-terminal
CC is critical for this aggregation enhancing effect. Further studies
with recombinant proteins demonstrated that the N-terminal CC
of MED15 (MED15CC) alone is sufficient to promote spontane-
ous ATXN1 aggregation in cell-free assays. We also observed that
a hybrid Pum1-MED15CC fusion protein potently enhances
ATXN1 aggregation in mammalian cells, while such an effect was
not observed with the wild-type Pum1 protein. Finally, cell-based
assays revealed that a truncated MED15 fragment lacking the N-
terminal CC (MED15DCC) in contrast to the wild-type protein
does not promote spontaneous ATXN1 aggregation. Together,
this supports the hypothesis that CC domains in interacting
proteins are critical for stimulation of spontaneous ATXN1
aggregation. The potential implications of these results for the
pathogenesis of polyQ disorders and the development of novel
therapeutic strategies are discussed.
Results
Selection of human polyQ toxicity and aggregation
modulators
Previously, proteins that modify the toxicity and aggregation of
different polyQ-containing disease proteins have been identified
using various model organisms, including Caenorhabditis elegans
[23,24], Drosophila melanogaster [17–20,22,25] Saccharomyces cerevisiae
[21,26] and Mus musculus [27]. We selected 192 human
homologues of known modifiers identified in lower organisms
according to information in the HomoloGene database [28]. In
addition, 45 human proteins that associate with polyQ disease
proteins in yeast two-hybrid (Y2H) and co-immunoprecipitation
assays were chosen [29], because modulators of polyQ toxicity and
aggregation are reportedly enriched among direct interaction
partners of disease proteins [30]. In total, 237 genes encoding
potential human modulator proteins were defined, 202 of which
(87%) were available as full-length cDNAs for modifier screens in a
cell model system (Table S1). The selected cDNAs were cloned
into the mammalian expression vector pCMV-FLAG using the
GATEWAY technology [31]; the identity of genes was confirmed
by DNA restriction and sequencing.
For expression analysis, 25 plasmids were randomly selected
and transfected into COS-1 cells. Synthesis of N-terminally
FLAG-tagged recombinant fusion proteins was verified by SDS-
PAGE and immunoblotting. We verified 22 of 25 randomly
selected plasmids (88%) to express FLAG-tagged proteins at
approximately the expected size in mammalian cells (Figure S1),
suggesting that most constructs were suitable for modulator
screening in cell-based assays.
Identifying modulators of YFP-ATXN1Q82NT toxicity and
aggregation
First, a cell-based assay for the detection of human proteins that
influence the toxicity of an N-terminal, aggregation-prone mutant
ATXN1 fragment was established (Figure S2A). Plasmids encod-
ing YFP-tagged truncated ATXN1 fusion proteins with non-
pathogenic or pathogenic polyQ tracts (YFP-ATXN1Q30NT and
ATXN1Q82NT) were constructed and transiently transfected into
Author Summary
Spinocerebellar ataxias (SCAs) are a group of inherited
neurodegenerative diseases with around 30 subtypes,
which are characterized by a progressive loss of cerebellar
neurons. Neuronal death has been linked to the aggrega-
tion of mutated disease-causing proteins, such as ataxin-1
(ATXN1). Pathogenic ATXN1 contains an elongated gluta-
mine stretch, which triggers spontaneous misfolding and
self-assembly of the protein into aggregates. Earlier studies
in lower organisms have discovered many non-human
proteins that alter aggregation and/or toxicity of mutant
ATXN1. Here, we combine an experimental screening
approach with bioinformatics to find human proteins that
modulate aggregation and toxicity of ATXN1. We identi-
fied 21 proteins affecting mutant ATXN1 in mammalian
cells. Further characterization revealed that enhancers of
ATXN1-mediated toxicity contain a-helical coiled-coil
domains as structural motifs, while suppressors do not.
Detailed studies with the ATXN1 interacting proteins
MED15 and Pum1 finally demonstrated that coiled-coil
domains are indeed critical for the aggregation and
toxicity promoting effects of human proteins. Our study
contributes to a deeper understanding of ATXN1 aggre-
gation and SCA1 pathogenesis and highlights potential
therapeutic targets for further investigations.
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COS-1 cells. After 48 h toxicity was monitored using a standard
caspase-3/7 assay. We observed that caspase-3/7 activity was ,2-
fold higher in cells with pathogenic YFP-ATXN1Q82NT than in
cells with non-pathogenic YFP-ATXN1Q30NT or the control
protein YFP (Figure 1A), indicating that the toxicity of ATXN1
fusion proteins in COS-1 cells is polyQ length dependent.
Next, we examined whether the proteins YFP-ATXN1Q30NT
and YFP-ATXN1Q82NT spontaneously form SDS-stable protein
aggregates in COS-1 cells using a filter retardation assay [32]. This
method allows the quantification of large SDS-stable protein
aggregates, whereas soluble monomers and small oligomers of
polyQ disease proteins are not detectable. We found that COS-1
cells overproducing YFP-ATXN1Q82NT contain insoluble protein
aggregates after 48 h, while such structures were not observed in
cells overproducing YFP-ATX1Q30NT (Figure 1B). This supports
previously published studies that ATXN1 fragments with patho-
genic polyQ tracts form SDS-stable protein aggregates in
mammalian cells [16].
The formation of insoluble YFP-tagged ATXN1Q30NT and
YFP-ATXN1Q82NT aggregates was also examined by confocal
microscopy and quantified with a high content fluorescence
imaging system (Figure S2B and S2C), showing both proteins to
form similar numbers of cytoplasmic inclusion bodies in COS-1
cells. Thus, both YFP-ATXN1Q30NT and YFP-ATXN1Q82NT
seem to be aggregation-prone proteins. However, SDS-stable
protein aggregates, detectable by filter retardation assays, are only
observed with pathogenic YFP-ATXN1Q82NT (Figure 1B).
Finally, we investigated whether the expression levels of YFP-
tagged ATXN1 fusion proteins with pathogenic and non-
pathogenic polyQ tracts are similar in COS-1 cells. Soluble
(supernatant) and insoluble protein fractions (pellet) were prepared
from crude COS-1 cell extracts by centrifugation and analyzed by
SDS-PAGE and immunoblotting (Figure 1C and 1D). We found
that the non-pathogenic protein YFP-ATXN1Q30NT is produced
at higher amounts in COS-1 cells than the pathogenic protein
YFP-ATXN1Q82NT, indicating that the observed increase in
caspase-3/7 activity in YFP-ATXN1Q82NT overproducing cells
(Figure 1A) is not caused by a simple dosage effect. These
investigations also confirmed the results obtained by immunoflu-
orescence microscopy (Figure S2B and S2C), indicating that both
YFP-ATXN1Q30NT and YFP-ATXN1Q82NT form similar
amounts of insoluble protein aggregates in COS-1 cells.
The screening strategy for YFP-ATXN1Q82NT toxicity mod-
ifiers in cell-based assays is schematically shown in Figure S3.
COS-1 cells were co-transfected with pairs of plasmids encoding
toxic YFP-ATXN1Q82NT and one of the 202 selected modulator
proteins. After 48 h caspase-3/7 activity was quantified in cell
extracts. Modulators that enhanced or suppressed YFP-
ATXN1Q82NT toxicity compared to the control plasmid
pFLAG-GW in three independent experiments by at least 20%
were selected. Hits from primary screens were systematically re-
tested in a control toxicity assay, monitoring the effect of
modulator proteins on caspase-3/7 activity in the absence of
YFP-ATXN1Q82NT (Figure S3). Using this approach, 21 human
proteins were identified that only influence caspase-3/7 activity in
mammalian cells in the presence of YFP-ATXN1Q82NT
(Figure 1E and Table S2). Of these, 19 are human homologues
of known modifiers of polyQ toxicity or aggregation in lower
model organisms [19,20,24]. Two proteins (Crk and Lin-10) were
previously identified as ATXN1 interaction partners in yeast two-
hybrid screens [29]. We found that over-production of 12 of these
proteins significantly enhanced YFP-ATXN1Q82NT-mediated
toxicity in COS-1 cells, while 9 proteins were suppressors of
toxicity. Overproduction of all identified 21 modifier proteins in
COS-1 cells was confirmed by SDS-PAGE and immunoblotting
(Figure S4).
Next, a membrane filter retardation assay [32] was utilized to
examine the effects of toxicity modulators on YFP-ATXN1Q82NT
aggregation. COS-1 cells were co-transfected with pairs of
plasmids encoding the modulators and YFP-ATXN1Q82NT.
Formation of insoluble aggregates was quantified after 48 h by
filtration of cell extracts through a cellulose acetate membrane. We
found that 15 (71%) of 21 tested proteins also significantly
influence YFP-ATXN1Q82NT aggregation in cell-based assays
(Figure 1F and Table S2), suggesting that the phenomena of
toxicity and aggregation are causally linked. Production of 13
proteins enhanced YFP-ATXN1Q82NT aggregation in COS-1
cells, while two proteins acted as aggregation suppressors.
We also systematically compared the results from toxicity and
aggregation assays to identify proteins with different combined
effects (Figure 1G). We found that 9 of the 21 tested modulator
proteins (43%) enhance both YFP-ATXN1Q82NT toxicity and
aggregation in COS-1 cells. Three proteins were identified that
enhance YFP-ATXN1Q82NT toxicity, but do not significantly
affect polyQ-mediated protein aggregation (Figure 1G). Overpro-
duction of two proteins – the proteasome subunit beta type-6
(PSMB6) and the small nuclear ribonucleoprotein polypeptide B
(SmB) - decreased both YFP-ATXN1Q82NT toxicity and aggre-
gation in cell assays, while three proteins were identified that
reduced toxicity but did not significantly affect polyQ-mediated
protein aggregation. Finally, four proteins (DNAJB4, AFG3L2,
Nek8 and Crk) caused a reduction of YFP-ATXN1Q82NT toxicity
but at the same time increased YFP-ATXN1Q82NT aggregation
(Figure 1E–1G), suggesting that the deposition of polyQ-contain-
ing proteins is beneficial for mammalian cells under certain
cellular conditions.
Finally, we also examined whether the identified toxicity
modulators are specific for the YFP-ATXN1Q82NT fusion
protein. To address this question a cell-based toxicity and
aggregation assay for the unrelated polyQ disease protein ATXN3
(YFP-ATXN3Q73) was established (Figure S5A and S5B) and
applied for systematic modifier testing. COS-1 cells were co-
transfected with pairs of plasmids encoding the toxic YFP-
ATXN3Q73 fusion protein and one of the 21 selected modulator
proteins; after 48 h caspase-3/7 activity in cell extracts was
quantified. Strikingly, we found that only four (P0, Vps4B, Ran,
Nek8) of the 21 previously identified YFP-ATXN1Q82NT toxicity
modulators (19%) influenced YFP-ATXN3Q73 toxicity in cell-
based assays (Figure S5C and Table S2), indicating that most
proteins are specific for pathogenic ATXN1. Two of the tested
modulators (Vps4B and Ran) also enhanced YFP-ATXN3Q73
protein aggregation as shown in Figure S5D.
RNAi knockdown studies in cell-based assays and
transgenic flies confirm the effects of modulator proteins
on ATXN1-mediated toxicity
To investigate whether reduced levels of endogenous modulator
proteins influence YFP-ATXN1Q82NT-induced toxicity, siRNA
gene silencing experiments were performed in COS1 cells. In
these experiments, we focused exclusively on the target genes
identified in earlier cell-based overexpression studies (Figure 1E).
Mammalian cells overproducing YFP-ATXN1Q82NT were treat-
ed with siRNAs and caspase-3/7 activity in protein extracts was
quantified after 48 h. siRNAs that increased caspase-3/7 activity
in the absence of YFP-ATXN1Q82NT in control experiments
were not considered for further knock-down experiments (data not
shown). We systematically tested 15 selected siRNAs in cell-based
assays, 10 of which (67%) reproducibly influenced the toxicity of
Misfolding and Toxicity Modifiers of Mutant ATXN1
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Figure 1. Identification of ATXN1 toxicity and aggregation modifiers using cell-based assays. (A) Relative caspase 3/7 activity change
induced by overproduction of proteins YFP-ATXN1Q30NT or YFP-ATXN1Q82NT in COS-1 cells compared to YFP overproducing cells. Caspase 3/7
activity was significantly increased in cells producing pathogenic YFP-ATXN1Q82NT compared to non-pathogenic YFP-ATXN1Q30NT (Student’s t-test,
** p,0.01, n = 3). Error bars indicate SD. (B) Detection of SDS insoluble protein aggregates by filter retardation assay. The protein YFP-ATXN1Q82NT
but not YFP-ATXN1Q30NT forms SDS-stable protein aggregates in COS-1 cells. Equal amounts of total protein were loaded. FLAG control protein was
set to 100%. (C) Western blot detection of YFP-ATXN1Q30NT and YFP-ATXN1Q82NT fusion proteins in total COS-1 cell extracts, supernatant and pellet
samples. The pellet samples were dissolved in 8 M urea. Proteins were detected using an anti-GFP monoclonal antibody (Sigma). Actin protein levels
were used as a loading control; Abbreviations: TL - total lysate; P – pellet; Sup – supernatant. (D) Quantification of YFP-tagged ATXN1 fusion proteins
using the AIDA densitometry software. Abbreviations: TL - total lysate; P – pellet; Sup – supernatant. (E) Effects of modifier proteins on YFP-
ATXN1Q82NT-induced cellular toxicity. 12 proteins were defined as enhancers and 9 as suppressors of YFP-ATXN1Q82NT toxicity. (F) Effects of modifier
proteins on YFP-ATXN1Q82NT aggregation monitored by filter retardation assays. 15 of 21 YFP-ATXN1Q82NT toxicity modulators also influence polyQ-
mediated protein aggregation. Data is shown as mean 6 SD from three independent experiments, which were performed in triplicates. Student’s t-
tests were used for statistical comparisons, p,0.05. (G) A comparison of modifier effects on YFP-ATXN1Q82NT cytotoxicity and aggregation.
doi:10.1371/journal.pgen.1002897.g001
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YFP-ATXN1Q82NT (Figure 2A and Table S3). 9 siRNAs
increased cellular toxicity, while one molecule decreased it. The
knock-down of target gene expression was confirmed by qRT-
PCR (Figure S6), confirming that upon siRNA treatment mRNA
levels were reduced by ,50–90%. A comparison of the results
from siRNA knock-down and cDNA overexpression revealed that
in eight of ten cases, knock-down of target genes had the opposite
effect to gene overexpression on YFP-ATXN1Q82NT toxicity
(Figure 2A). However, we also found that both siRNA knock-down
and overexpression of genes (C16orf70 and RAN) could promote
the toxicity of YFP-ATXN1Q82NT in cells.
Finally, we investigated whether knock-down of target genes
influences the toxicity of full-length, pathogenic ATXN1
(ATXN1Q82) in the well-established SCA1 transgenic fly model
[19]. We selected the proteins MED15 and Nek8 for these studies
as they reproducibly influenced the toxicity of pathogenic YFP-
ATXN1Q82NT in several cell-based assays (Figure 1E and
Figure 2A). We systematically crossed transgenic SCA1 flies with
UAS-RNAi flies [33] and subsequently examined the degeneration
of photoreceptors using scanning electron microscopy. We found
that overproduction of ATXN1Q82 caused a pronounced
neurodegenerative eye phenotype (Figure 2B), as previously
reported [19]. However, ATXN1Q82-mediated eye degeneration
was reduced in flies expressing the MED15 RNAi construct
(Figure 2B), confirming the results from our cell model studies
(Figure 2A). The opposite effect was observed in ATXN1Q82 flies
that express a niki (Nek8 homologue) RNAi construct (Figure 2B),
suggesting that expression of this gene protects against the toxicity
in SCA1 transgenic flies. An eye phenotype was not detected when
control wild-type flies with MED15 or niki RNAi constructs were
analyzed (data not shown).
Functional and structural properties of modulators
influencing YFP-ATXN1Q82NT toxicity
First, we investigated the potential functional roles of the 21
identified YFP-ATXN1Q82NT toxicity modulators using the
EASE program [34]. This tool identifies over-represented
functional categories in gene lists. We observed that proteins
involved in protein folding, RNA binding, translation, ribosome
function, membrane fusion and protein biosynthesis are signifi-
cantly enriched in the set of YFP-ATXN1Q82NT toxicity
modulators (adjusted p-value,0.05; Figure 3A). A detailed
examination of the available literature information using PubMed
data largely confirmed the results from the EASE analysis (Table
S4). Among the most relevant functions of the 21 toxicity
modulators, we found ribosomal proteins (P0, L8, L10 and RPSA)
[35], well known regulators of translation and/or transcription
(EIF2G, Pum1 or MED15) [36–38], proteins involved in mRNA
splicing (Sm-D2 and SmB), vesicle trafficking (Ran, Vps4B,
aSNAP and ATP6V1E), protein degradation (PSMD7 and
PSMB6), protein folding (DNAJB4 and AFG3L2) and ATP
metabolism (ATP5F1) (Table S4), confirming earlier reports that
these cellular processes influence the toxicity of polyQ disease
proteins [18,24].
Recent studies have postulated that coiled-coil (CC) domains
are critical for the spontaneous aggregation and toxicity of polyQ
disease proteins [39,40]. We therefore investigated computation-
ally whether the identified YFP-ATXN1Q82NT toxicity modula-
tors contain such aggregation-promoting domains. Using the tool
COILS [41], we predicted that 6 out of 21 proteins (28.6%) most
likely contain CC domains (Table S5). Strikingly, we also found
that among 12 toxicity enhancers, 6 (50%) contain putative CC
domains (ATP6V1E, MED15, aSNAP, ATP5F1, PSMD7 and
Vps4B), while this domain was not detected in any of the toxicity
Figure 2. Reduced levels of modifier proteins influence the
cytotoxicity of pathogenic ATXN1 in model systems. (A)
Comparison of modifier gene effects on YFP-ATXN1Q82NT-induced
toxicity in cell-based cDNA overexpression and siRNA knock-down
experiments. Most modifiers in cDNA overexpression studies show
opposing effects on YFP-ATXN1Q82NT toxicity than modifiers in siRNA
knock-down experiments. Error bars indicate SD from three indepen-
dent experiments performed in triplicates. Student’s t-tests were used
for statistical comparisons, p,0.05. (B) Reduced levels of modifier
proteins influence the toxicity of pathogenic ATXN1 in transgenic flies.
RNAi knockdown of MED15 reduces ATXN1Q82-induced retinal
degeneration, while knockdown of niki (homologue of human NEK8)
increases the toxicity of the polyQ disease protein. The effects of
modifiers on Drosophila eyes are visualized by loss of pigmentation
(upper panel, optical microscopy), alterations in morphology of
ommatidia (middle panel, electron microscopy) and bristle disorgani-
zation (lower panel, 106 magnifications of electron microscopy
images). Drosophila eyes are shown from representative animals: a)
wild-type (+/+), b) GMR-GAL4;UAS-ATXN1Q82/+;UAS-Luciferase RNAi, c)
GMR-GAL4;UAS-ATXN1Q82/+; UAS-MED15 RNAi, and d) GMR-GAL4;UAS-
ATXN1Q82/+;UAS-niki RNAi.
doi:10.1371/journal.pgen.1002897.g002
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Figure 3. Specific functional categories and structural domains are over-represented among YFP-ATXN1Q82NT toxicity modifiers.
(A) Functional annotation of YFP-ATXN1Q82NT toxicity modifiers was carried out using the EASE program. Genes encoding proteins involved in
protein folding, RNA binding, translation, ribosome function, membrane fusion and protein biosynthesis are over-represented among YFP-
ATXN1Q82NT toxicity modifiers compared to the human genome (Fisher’s exact test, p,0.05). (B) Proteins with coiled-coil domains are significantly
enriched among YFP-ATXN1Q82NT toxicity enhancers but not among suppressors (p = 0.0093; Chi-square test). Coiled-coil domains in modifier
proteins were predicted using the COILS program (probability 0.8–1). Numbers of coiled-coil domain containing proteins were compared to the
human proteome (73,427 proteins, Swiss-Prot database). (C) The human MED15 protein contains a conserved N-terminal Q-rich region with short
polyQ tracts. The graphs represent the amounts of glutamines (Qs) in a window of 50 amino acids (blue line) or the amount of consecutive polyQ
sequences (.5 Qs) in a window of 50 amino acids (red line). Abbreviations: hs – Homo sapiens, mm – Mus musculus, dm – Drosophila melanogaster, ce
– Caenorhabditis elegans. (D) The human Pum1 protein contains conserved Q-rich regions but does not contain short polyQ tracts. For species
abbreviations see C.
doi:10.1371/journal.pgen.1002897.g003
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suppressors (9 proteins). This suggests that CC domains contribute
to the toxicity promoting effects of modifier proteins in mammalian
cells. We also observed that, compared to the human proteome,
proteins with CC domains are significantly enriched among
enhancers of YFP-ATXN1Q82NT toxicity (p= 0.0093, Chi-square
test; Figure 3B), supporting the importance of this observation.
Previous studies have also demonstrated that proteins with
short, non-pathogenic polyQ tracts bind to neurodegenerative
disease proteins with long, pathogenic polyQ tracts and influence
their aggregation propensity in vitro and in vivo [42,43]. This
suggests that proteins with longer regions of polar amino acids
might function as modifiers of polyQ-mediated ATXN1 misfold-
ing and toxicity. Among the 21 human toxicity modifiers, we
identified only two proteins (MED15 and Pum1) with Q-rich
regions by computational sequence analysis (Figure 3C and 3D).
MED15 contains a single, N-terminal Q-rich region with multiple
short polyQ (5–16 Qs) tracts, which are also well conserved in
orthologous proteins of lower organisms. Multiple conserved Q-
rich regions were also detected in the protein Pum1. However, in
this protein no polyQ tracts were detected (Figure 3C and 3D),
suggesting that these Q-rich domains might have different
functions and biochemical properties than the one in MED15.
Finally, we also investigated whether the Q-rich proteins MED15
and Pum1 contain conserved CC domains. Interestingly, we
predicted that MED15 contains a long N-terminal CC domain,
which is conserved in higher organisms (Figure S7A). Such a domain,
however, was not predicted for Pum1 (Figure S7B). Obviously, these
Q-rich proteins, which show opposite effects on YFP-ATXN1Q82NT
toxicity in cell-based assays (Figure 1E and Figure 2A), are structured
differently with different functional consequences.
The proteins MED15 and Pum1 interact with full-length
ATXN1 in cell-based assays
Previous investigations suggest that ATXN1 interacts with the
human proteins Pum1 and MED15 [44]. To substantiate these
observations, we examined whether the proteins associate with
full-length wild-type or mutant ATXN1 (ATXN1Q30 or
ATXN1Q82) using a LUminescence-based Mammalian IntER-
actome co-immunoprecipitation assay (LUMIER) [45]. The
principle of this method is shown in Figure 4A and Figure S8.
Full-length ATXN1 fusion proteins tagged with protein-A and
Renilla luciferase (PA-RL-ATXN1Q30 and PA-RL-ATXN1Q82)
were co-produced in HEK293 cells together with firefly luciferase
(FL)-tagged Pum1 or MED15 (FL-Pum1 or FL-MED15). After
48 h protein complexes were co-immunoprecipitated with IgG-
coated magnetic beads. Interactions were detected by quantifica-
tion of firefly luciferase luminescence from co-immunoprecipitated
protein complexes (Figure S8). We found that both Pum1 and
MED15 specifically interact with both ATXN1Q30 and
ATXN1Q82 in mammalian cells (Figure 4B; R-op and R-ob
ratios .1.5), confirming previously published reports [44]. A
similar result was obtained with the protein U2AF2 (positive
control) [29]. Production of bait and prey proteins in mammalian
cells was verified by the quantification of Renilla and firefly
luciferase activities in cell extracts before the co-immunoprecip-
itation step (Figure S9). Thus, our studies support previous
observations that both MED15 and Pum1 interact with wild type
and mutant full-length ATXN1 proteins in mammalian cells.
MED15 and Pum1 directly modulate polyQ-mediated
ATXN1 aggregation in cell-free assays
We next investigated whether MED15 and Pum1 directly
influence polyQ-mediated ATXN1 aggregation in cell-free assays.
The principle of the in vitro ATXN1Q82 aggregation assay with
purified proteins is schematically shown in Figure S10A.
Recombinant proteins were produced as GST- and His-tagged
fusions (GST-ATXN1Q82, His-MED15 and His-Pum1) in E. coli
and purified to ,90% homogeneity by affinity chromatography
(Figure S10B). GST-ATXN1Q82 fusion protein was incubated
with PreScission (PP) protease and the modifier proteins His-
MED15 or His-Pum1; the formation of SDS-stable ATXN1Q82
aggregates was quantified after 24 and 48 h using a filter
retardation assay [46]. PP was added to the reactions to remove
the GST tag and to initiate spontaneous ATXN1Q82 aggregation
[47]. We found that an equimolar concentration of His-MED15
stimulated de novo ATXN1Q82 aggregation in vitro, while His-
Pum1 had the opposite effect (Figure 5A and 5B), indicating that
Figure 4. The modulator proteins MED15 and Pum1 interact
with wild-type and mutant ATXN1. (A) Schematic representation of
a LUMIER co-immunoprecipiation assay. The protein A (PA)-Renilla
luciferase (RL)-tagged bait (PA-RL-Y) and the firefly luciferase (FL)-
tagged prey proteins (FL-X, modifier) were co-produced in HEK293 cells.
After co-immunoprecipitation from cell lysates the interaction between
bait and prey fusion proteins was monitored by quantification of firefly
luciferase activity in protein complexes. Quantification of Renilla
luciferase activity in precipitated protein complexes indicates the
immunoprecipitation of bait protein. Abbreviations: PA – protein A tag;
RL – Renilla luciferase; FL – firefly luciferase; X – prey protein; Y – bait
protein; TF – transfection of cells; IP –immunoprecipitation; LA –
luminescence assay; LS – luminescence signal. (B) The human proteins
U2AF2, MED15 and Pum1 interact with both wild-type and mutant
ATXN1 fusion proteins in LUMIER co-immunoprecipitation assays. The
R-op and R-ob binding ratios (see Figure S8) of .1.5 indicate that the
proteins U2AF2, MED15 and Pum1 specifically interact with ATXN1Q30
or ATXN1Q82 in mammalian cells.
doi:10.1371/journal.pgen.1002897.g004
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both proteins directly influence spontaneous polyQ-mediated
ATXN1 aggregation. An aggregation promoting or inhibiting
effect was also observed when different concentrations of MED15
and Pum1 were added to reactions, respectively, indicating that
the proteins influence ATXN1Q82 aggregation in a concentra-
tion-dependent manner (Figure S11A and S11B).
A short N-terminal coiled-coil domain of MED15 is
sufficient to promote ATXN1Q82 aggregation in vitro
Our data with cell-free and cell-based aggregation assays suggest
that the conserved N-terminal CC domain in MED15 (Figure
S7A) is critical for its aggregation-promoting effect on ATXN1. To
investigate this possibility, a GST-tagged MED15CC fragment (aa
141–316; GST-MED15CC, Figure 5C) was produced in E. coli,
purified by affinity chromatography and examined by circular
dichroism (CD) spectroscopy [48]. The far-UV spectrum for
MED15CC was acquired by subtraction of the CD spectrum
of the control protein GST from that of the fusion protein
GST-MED15CC (Figure 5D). The putative conformation of
MED15CC was determined using the K2D2 secondary structure
program [49]. We predicted that MED15CC is mainly an alpha-
helical (55%) protein with a small percentage of beta-sheets (7%).
Previous studies revealed that ratios of mean residue ellipticities at
wavelengths 222 and 208 nm ([h]222/[h]208) above 1.0 indicate
coiled-coil conformation [50,51]. We determined that MED15CC
has a [h]222/[h]208 ratio of 1.078, indicating that it forms a
coiled-coil structure in vitro. For comparison, we observed a
[h]222/[h]208 ratio of 0.84 for the control protein GST whose
alpha-helical structure is known to lack coiled coils [52]. Thus, our
structural investigations suggest that MED15CC has a character-
istic alpha-helical CC structure.
Finally, we investigated whether MED15CC directly influences
spontaneous ATXN1Q82 aggregation in cell-free assays. GST-
ATXN1Q82 fusion protein (2 mM) was incubated with PP and
GST-MED15CC (2 or 7 mM); the formation of SDS-stable
ATXN1Q82 aggregates was quantified after 24 and 48 h by filter
retardation assay (Figure 5E and Figure 5F). We found that the
fusion protein GST-MED15CC in a concentration-dependent
manner promoted spontaneous ATXN1Q82 aggregation in vitro.
A hybrid Pum1-MED15CC protein promotes ATXN1
aggregation in cell-based assays
Our data indicate that MED15CC alone is sufficient to promote
spontaneous ATXN1Q82 aggregation in cell-free assays (Figure 5E
and 5F). This suggests that an insertion of this domain into Pum1
(an ATXN1Q82 aggregation suppressor, Figure 5A) should
increase its ability to promote ATXN1 aggregation. To test this
hypothesis, we generated a plasmid for the production of a
mCherry-tagged Pum1-MED15CC hybrid protein (Figure 6A).
The MED15CC fragment was inserted in Pum1 in a putative
unstructured region at amino acid 292, to avoid disrupting a
folded protein domain. We also generated plasmids for the
production of the mCherry-tagged proteins MED15, Pum1,
S100B, STUB1 and luciferase, which were used as controls.
First, the effects of the recombinant proteins on spontaneous
YFP-ATXN1Q82NT aggregation were investigated (Figure 6B).
The mCherry-tagged proteins were co-produced with YFP-
ATXN1Q82NT in a neuroblastoma cell model and formation of
insoluble polyQ-containing protein aggregates was quantified after
48 h by high content fluorescence imaging [53]. We found that co-
production of Pum1-MED15CC promoted YFP-ATXN1Q82NT
aggregation at levels significantly higher than Pum1 or the control
protein luciferase, supporting the hypothesis that the MED15 CC
domain is critical for aggregation stimulation. An aggregation-
promoting effect was also obtained with the proteins MED15 and
STUB1, while S100B showed the opposite effect, supporting
previously published studies [54].
Next, we investigated whether the protein Pum1-MED15CC
can also promote the aggregation of a full-length ATXN1 protein
with a pathogenic polyQ tract (YFP-ATXN1Q82). In contrast to
YFP-ATXN1Q82NT, this protein forms nuclear protein aggre-
gates in mammalian cells (Figure S12A–S12D). We found that
Pum1-MED15CC enhanced spontaneous YFP-ATXN1Q82 ag-
gregation, while Pum1 had no effect, confirming the results
obtained with the truncated ATXN1 fragment (Figure 6B).
Finally, we also investigated the association of Pum1-MED15CC
and Pum1 with YFP-ATXN1Q82NT by confocal microscopy
(Figure 6C). We found that both mCherry-tagged proteins
co-localize with perinuclear, cytoplasmic YFP-ATXN1Q82NT
aggregates in COS-1 cells, confirming the results that Pum1 directly
interacts with ATXN1 and influences its spontaneous aggregation
process (Figure 5A). The expression of mCherry- and YFP-tagged
fusion proteins in mammalian cells was also verified by SDS-PAGE
and immunoblotting (Figure S12D and Figure S13).
The protein MED15DCC does not promote YFP-
ATXN1Q82 aggregation and toxicity in cell-based assays
We also examined whether a truncated MED15 fragment
lacking the N-terminal CC domain (MED15DCC) influences
spontaneous ATXN1 aggregation (Figure 7A and 7B). The
mCherry-tagged proteins MED15 and MED15DCC were co-
produced with YFP-ATXN1Q82 in neuroblastoma cells and the
formation of polyQ-containing protein aggregates was quantified
after 48 h by high content fluorescence imaging [53]. We found
that co-production of full-length MED15 increased the deposition
of insoluble YFP-ATXN1Q82 aggregates in mammalian cells
(Figure 7B), confirming the results in cell-free aggregation assays
(Figure 5A). In contrast, YFP-ATXN1Q82 aggregation was not
increased in cells co-producing the truncated protein
MED15DCC, indicating that the N-terminal CC domain in
MED15 indeed is critical for the stimulation of ATXN-1
aggregation.
Next, we used the established COS-1 cell model to investigate
the effects of MED15 and MED15DCC on YFP-ATXN1Q82
toxicity. FLAG-tagged MED15 and MED15DCC fusion proteins
were co-produced with YFP-ATXN1Q82 in COS-1 cells and after
48 h the caspase-3/7 activity was quantified in cell extracts. We
found that YFP-ATXN1Q82 toxicity was significantly increased in
the presence of full-length MED15 protein but not in the presence
of the truncated fragment MED15DCC (Figure 7C), indicating
that the CC domain in MED15 influences both aggregation and
toxicity of mutant ATXN-1 in mammalian cells.
Finally, we examined whether the N-terminal CC domain in
MED15 influences the association of the protein with YFP-
ATXN1Q82 in mammalian cells using confocal microscopy
(Figure 7D). We observed that full-length mCherry-tagged
MED15 fusion protein readily co-localized with YFP-ATXN1Q82
aggregates in intranuclear inclusion bodies. However, co-localiza-
tion was diminished with the mCherry-tagged protein
MED15DCC, indicating that the N-terminal CC domain in
MED15 is critical for the binding of the fusion protein to YFP-
ATXN1Q82 (Figure 7D). The expression of mCherry- and FLAG-
tagged fusion proteins in mammalian cells was confirmed by SDS-
PAGE and immunoblotting (Figure S13).
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Discussion
Cell-based assays detect ATXN1 toxicity and aggregation
modifiers
In previous studies a large number of modifier proteins have
been identified that influence misfolding or toxicity of polyQ
disease proteins such as huntingtin, ataxin-1 or ataxin-3
[17,19,26]. These modifiers give important hints as to which
cellular pathways are altered in polyQ diseases; however, they do
not immediately allow a comprehensive mechanistic understand-
ing of disease processes in neurons or patient brains. It often
remains unclear whether modifiers identified in model organisms
have a direct or indirect effect on misfolding and aggregation of
polyQ disease proteins and whether human homologues of such
proteins are also effective.
In this study, ,200 human modifier proteins were predicted
using available information from genetic screens in lower model
organisms [55]. These proteins were systematically tested for their
effects on the toxicity and aggregation of a pathogenic ATXN1
fragment (YFP-ATXN1Q82NT) in cell-based assays. Our investi-
gations revealed 21 modulators that reproducibly enhanced or
reduced the toxicity of YFP-ATXN1Q82NT (Figure 1E). Most of
these proteins (71.4%) also showed a strong effect on polyQ-
mediated ATXN1 protein aggregation in filter retardation assays
(Figure 1F), supporting previous findings that protein misfolding is
associated with dysfunction and toxicity in mammalian cells
[17,24]. Experiments involving ATXN3, an unrelated polyQ
disease protein [56], revealed that most toxicity modifiers were
specific for YFP-ATXN1Q82NT, indicating that polyQ tracts,
which are present in both ATXN1 and ATXN3, did not dominate
modifier selection. Overall, our studies demonstrate that cell-based
cDNA over-expression assays allow the identification of disease
protein-specific toxicity and aggregation modifiers.
Figure 5. The N-terminal CC domain in MED15 enhances
polyQ-mediated ATXN1 aggregation in cell-free assays. (A)
Effects of His-tagged modifier proteins MED15 and Pum1 on
spontaneous ATXN1Q82 aggregation in vitro. SDS-insoluble ATXN1Q82
aggregates were detected by filter assay. The protein MED15 enhanced
spontaneous ATXN1Q82 aggregation while Pum1 showed the opposite
effect. The protein GST was used as a control. Formation of SDS-
insoluble ATXN1Q82 protein aggregates was detected by filter assay
using the anti-ATXN1 antibody SA4645. (B) Quantification of ATXN1Q82
aggregates on filter membranes was performed using the AIDA
densitometry software. The ATXN1Q82 immunoreactivity of samples
obtained with the control protein GST was set to 100% (48 h). Error bars
represent SD of three independent experiments. (C) Schematic view of
the cloning strategy for the generation of the MED15CC fragment for in
vitro aggregation experiments. A Gateway compatible entry plasmid
encoding the N-terminal coiled-coil domain of MED15 (MED15CC) was
constructed. (D) Far-UV CD spectra of the GST-tagged MED15CC fusion
protein and GST. Both proteins adopt a typical alpha-helical conforma-
tion. A ratio of mean residue ellipticities ([h]222/[h]208) of 1.078948
indicates that MED15CC has a coiled-coil conformation. (E) The GST-
tagged MED15CC fusion protein stimulates spontaneous ATXN1Q82
aggregation in cell-free assays. The formation of SDS-insoluble
ATXN1Q82 aggregates was detected by filter retardation assays using
the anti-ATXN1 antibody SA4645. (F) Quantification of insoluble
ATXN1Q82 aggregates retained on filter membranes was performed
using the AIDA densitometry software. The immunoreactivity of
insoluble ATXN1Q82 aggregates in control samples with GST (48 h)
was set to 100%. Error bars represent SD of three independent
experiments.
doi:10.1371/journal.pgen.1002897.g005
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Modulators of ATXN1 toxicity and aggregation play
important functional roles in a variety of cellular
processes
Using Gene Ontology information [34], we analyzed the
annotated cellular functions of YFP-ATXN1Q82NT toxicity
modifiers. We found that proteins involved in protein translation,
protein folding, RNA metabolism, membrane fusion and protein
biosynthesis were overrepresented among modifiers. This is in
agreement with previous observations from genetic screens in
model organisms [55]. Our observations are also in line with the
view that an interplay between different cellular pathways controls
Figure 6. A hybrid Pum1 fusion protein with a MED15 CC domain is a potent enhancer of mutant ATXN1 aggregation in cell-based
assays. (A) Schematic representation of the hybrid Pum1-MED15CC fusion protein. (B) Effects of mCherry-tagged proteins Pum1-MED15CC, Pum1,
MED15, S100B, STUB1 and luciferase on spontaneous YFP-ATXN1Q82NT aggregation in human neuroblastoma SH-EP cells. The formation of polyQ-
containing ATXN1 aggregates was quantified by fluorescence imaging after 48 h. Data is normalized to the total mCherry fluorescence intensity. The
proteins MED15, STUB1 and Pum1-MED15CC enhanced YFP-ATXN1Q82NT aggregation compared to Pum1 or the luciferase control protein (100%). A
suppression of YFP-ATXN1Q82NT aggregation was observed with the control protein S100B. Data is shown as mean 6 SD from three independent
experiments. Experiments were performed in triplicates. Student’s t-test was used for statistical comparisons, p,0.05. (C) Confocal microscopy
images of COS-1 cells co-transfected with pairs of plasmids encoding YFP-ATXN1Q82NT and mCherry-tagged Pum1 or Pum1-MED15CC. Nuclei were
stained with Hoechst 33342 (blue). YFP-ATXN1Q82NT aggregates were stained in green and mCherry-Pum1 or mCherry-Pum1-MED15CC in red color.
Both Pum1 and Pum1-MED15CC proteins co-localize with YFP-ATXN1Q82NT proteins.
doi:10.1371/journal.pgen.1002897.g006
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polyQ-mediated protein aggregation and proteotoxicity [57,58],
which balance protein biosynthesis, folding, translocation and
clearance.
Protein folding modulators. Previous studies in disease
model systems have demonstrated that overproduction of molec-
ular chaperones such as Hsp70 or Hsp40 efficiently reduce the
toxicity of polyQ disease proteins [22,59]. This effect can be
observed with chaperones in various species from bacteria to
human [60], indicating that protein folding pathways are highly
conserved and are a first line of cellular defense against the
accumulation of toxic misfolded proteins in all organisms. Our
studies support the thesis that molecular chaperones are key
players in protein homeostasis networks. We found that overpro-
duction of DNAJB4, a member of the Hsp40 chaperone
family [61], efficiently reduced the toxicity of pathogenic YFP-
ATXN1Q82NT in cell-based assays. Interestingly, this effect was
accompanied by an increase of SDS-insoluble ATXN1 aggregates,
indicating that high levels of DNAJB4 reduce cellular toxicity but
promote the assembly of polyQ-containing protein aggregates. A
similar result was obtained with the mitochondrial chaperone
AFG3L2 (Figure 1E and 1F). This protein belongs to the family of
ATP dependent AAA proteases [62], which regulate the degra-
dation of misfolded polypeptides in mitochondria. The importance
of AFG3L2 in maintaining cellular protein function is underscored
by the recent observation that mutations in this protein cause the
neurodegenerative disease SCA28 [63,64]. Thus, our data
establish a potential link between the pathogenesis in SCA1 and
SCA28 that needs to be further investigated genetically and
mechanistically.
Modulators of RNA synthesis and processing. Our
studies also suggest that some ATXN1 toxicity modifiers are
RNA-binding proteins, which are functionally involved in the
regulation of transcription and translation. For example, we
identified the RNA-binding protein Pum1 as an ATXN1 toxicity
modulator in cell-based assays. It functions as a repressor of
translation and most probably influences dendrite morphogenesis
and synaptic function in neurons [65]. Pumilio, the Drosophila
homologue of human Pum1, was previously identified as a potent
enhancer of ATXN1 toxicity in SCA1 transgenic flies [19]. In our
cell-based assays, however, human Pum1 functioned as a
suppressor of YFP-ATXN1Q82NT toxicity (Figure 1E). We
suggest that the CC domain, which can be computationally
predicted in the fly but not in the human protein (Figure S7B),
might be responsible for these opposing effects. CC domains are
well known mediators of protein-protein interactions [66,67],
suggesting that the CC in Pumilio might function as a template
that promotes the intermolecular association of aggregation-prone
ATXN1 molecules. However, more detailed comparative studies
with the fly and the human proteins are necessary to substantiate
this hypothesis.
Modulators of protein translation. Proteins involved in
translation were also overrepresented among ATXN1 toxicity
modifiers in this study (adjusted p-value,0.05; Figure 3A). This
includes ribosomal proteins such as P0 or L10 as well as regulators
of protein synthesis such as EIF2G [68]. The identification of
proteins that influence translation is not unexpected, as it is well
known that protein levels are critical for aggregation and toxicity
of polyQ disease proteins in cells [69]. Interestingly, the eukaryotic
translation initiation factor subunit B (EIF2G) was identified as a
potent suppressor of YFP-ATXN1Q82NT toxicity. This protein is
a component of the eukaryotic initiation factor 2 (eIF2), which
mediates tRNAmet binding to ribosomes and controls global
protein synthesis [70]. Previous studies have demonstrated that
stress kinases such as PKR, which are activated in brains of
patients with neurodegenerative diseases [71], can inactivate eIF2
function through phosphorylation. This leads to a reduction in
protein synthesis and the activation of cell death pathways [72].
Figure 7. Effects of MED15DCC on mutant ATXN1 aggregation
and cytotoxicity in cell-based assays. (A) Schematic representation
of the MED15DCC fusion protein. (B) Effects of mCherry-tagged proteins
MED15, MED15DCC and luciferase on spontaneous YFP-ATXN1Q82
aggregation in neuroblastoma SH-EP cells. The formation of YFP-
ATXN1Q82 aggregates was quantified by fluorescence imaging after
48 h. Data were normalized to the total mCherry fluorescence
intensities. Data is shown as mean 6 SD from three independent
experiments. Experiments were performed in triplicates. Student’s t-test
was used for statistical comparisons, p,0.05. (C) Effects of FLAG-tagged
fusion proteins MED15 and MED15DCC on YFP-ATXN1Q82-induced
cellular toxicity in COS-1 cells. YFP-ATXN1Q82 cytotoxicity was
increased in the presence of full-length MED15 but not in the presence
of the truncated fragment MED15DCC. Cells transfected with the
control plasmid pFLAG were used as a control (100%). (D) Confocal
microscopy images of COS-1 cells co-transfected with pairs of plasmids
encoding YFP-ATXN1Q82 and mCherry-tagged MED15 or MED15DCC.
Nuclei were stained with Hoechst 33342 (blue).
doi:10.1371/journal.pgen.1002897.g007
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Our results suggest that the toxicity suppressing effect of EIF2G in
cells with YFP-ATXN1Q82NT might be due to a re-activation of
eIF2 function, leading to improved protein translation and
reduced apoptosis.
Modulators of protein and vesicle trafficking. Our cell-
based toxicity assays also identified several modifiers with
important functions in protein and vesicle transport processes
(Table S4). This was not expected from previous modifier studies,
which showed that mainly molecular chaperones, RNA binding
proteins and transcription regulators influence the toxicity of
pathogenic ATXN1 or ATXN3 in lower model organisms [55].
We found, e.g., that the vacuolar sorting associated protein Vps4B
is a potent modulator of polyQ toxicity in cell-based assays. Vps4B
is an AAA ATPase mediating the transport of proteins from
endosomes to lysosomes [73]. Its function is tightly linked to the
endosomal sorting complex required for transport machinery
(ESCRT), a large membrane-associated protein complex, which is
also critical for efficient autophagy-mediated degradation of
misfolded proteins [74,75]. Recent studies indicate that mutations
in ESCRT proteins such as CHMP2B can cause neurodegener-
ation and the accumulation of misfolded proteins in neuronal cells
[75,76], supporting our observations that proteins with key
functions in vesicle transport processes influence aggregation and
toxicity of mutant ATXN1.
Structural characteristics of ATXN1 toxicity modifier
proteins
Recent studies indicate that alpha-helical coiled-coil (CC)
domains are critical for the spontaneous aggregation of Q/N-rich
yeast prions and polyQ disease proteins [39,40]. This suggests that
such domains, known to promote protein-protein interactions [67],
might also be present in modifier proteins and contribute to their
effects on ATXN1 aggregation and toxicity in cell-based assays. We
computationally predicted that 6 of 21 YFP-ATXN1Q82NT toxicity
modifiers contain CC domains (Table S5). In addition, we found
that CC domains are exclusively present in ATXN1 toxicity and
aggregation enhancers (Figure 3B), suggesting that they are critical
for this effect in mammalian cells. We hypothesized that proteins
with CC domains may enhance protein aggregation and toxicity
because they directly promote the intermolecular association of
ATXN1 molecules. To test this hypothesis, we purified the ATXN1
interacting proteins MED15 and Pum1 and investigated whether
they influence polyQ-mediated ATXN1 aggregation in cell-free
assays. We predicted that MED15 contains a large N-terminal CC
domain (Figure S7A), while such a domain was not detectable in the
Pum1 protein (Figure S7B). However, both proteins were found to
interact with ATXN1 in cell-based co-immunoprecipitation assays
(Figure 4B). In vitro aggregation studies with recombinant, purified
proteins revealed that the CC domain-containing protein MED15
stimulates spontaneous ATXN1Q82 aggregation, while such an
effect was not observed with the protein Pum1 lacking a CC domain
(Figure 5A and 5B).
Using CD spectroscopy, we confirmed that the computationally
predicted N-terminal CC domain in MED15 (MED15CC, aa
141–316) adopts a typical a-helical CC structure (Figure 5D).
Moreover, we examined whether this domain alone is sufficient to
promote ATXN1Q82 misfolding in cell-free aggregation assays.
We found that MED15CC similar to full-length MED15 is a
potent enhancer of polyQ-mediated protein aggregation in vitro,
supporting the hypothesis that this N-terminal domain is critical
for MED15-mediated stimulation of ATXN1 aggregation
(Figure 5E and Figure 5F). We also examined whether a hybrid
Pum1 protein with an N-terminal MED15CC fragment can
promote ATXN1 aggregation in cell-based assays. We observed
that in strong contrast to the wild-type Pum1 protein the hybrid
Pum1-MED15CC fusion is a potent ATXN1 aggregation
enhancer (Figure 6B and Figure S12A). Finally, we investigated
whether a truncated MED15 fragment lacking the N-terminal CC
domain (MED15DCC) influences mutant ATXN1 aggregation
and toxicity in cell-based assays. We observed that MED15DCC
in contrast to the wild-type protein does not promote ATXN1
aggregation and toxicity (Figure 7B and 7C). Thus, our cell-based
studies support the results obtained in cell-free assays, indicating
that the N-terminal a-helical CC region in MED15 is critical for
efficient stimulation of spontaneous protein aggregation [39].
Several lines of experimental evidence indicate that long polyQ
tracts in neurodegenerative disease proteins such as ATXN1 have
to undergo a conformational change before they can assemble into
insoluble protein aggregates [77,78]. While polyQ tracts in soluble
proteins often have a random coil or an a-helical conformation,
they adopt a characteristic b-sheet structure in insoluble protein
aggregates [79]. Thus, it is currently thought that a conforma-
tional switch from an a-helical to a b-sheet conformation controls
spontaneous polyQ-mediated protein aggregation [80]. Our
experiments indicate that interacting proteins with CC domains
such as MED15 can promote the spontaneous aggregation of
polyQ disease proteins, because they function as a template for the
efficient transition of helical domains to b-sheets. This view is also
supported by previous investigations, indicating that a-helical
structures are critical intermediates in the aggregation pathway of
b-sheet-rich amyloid structures [81]. We suggest that this
mechanism may have important implications for the development
of therapeutic strategies against polyQ diseases, because interac-
tion partners with CC domains are potent enhancers of abnormal
protein aggregation. Thus, higher concentrations of proteins with
CC domains in neurons might initiate the disease process, causing
progressive dysfunction of the cellular proteostasis network [82]. In
the long run, this might lead to cellular degeneration and the
activation of cell death pathways [57,82]. However, more detailed
studies investigating the potential dysregulation of CC domain-
containing proteins in neurons are necessary to fully understand
the impact of CC proteins on polyQ aggregation and toxicity in
cells.
Conclusions
Taken as a whole, our study shows that a strategy combining
bioinformatic and experimental approaches is useful for the
identification of human modifier proteins that influence the
toxicity and aggregation of pathogenic ATXN1. These modifiers
play a functional role in a variety of different cellular mechanisms
that are currently not very well understood. Further investigations
with human proteins and their homologues from lower model
organisms such as D. melanogaster or C. elegans are necessary to
elucidate the cellular processes that increase or reduce the toxicity
of pathogenic polyQ proteins. We suggest that a step-by-step
process of data integration and refinement as well as dissection of
molecular details in signaling cascades and cellular protein quality
control pathways will lead to the discovery of new drug targets and
therapeutic strategies, which can be tested in appropriate disease
models and patients with polyQ diseases.
Materials and Methods
Generation of Gateway entry plasmids
cDNA fragments encoding human proteins MED15CC (M141-
S316, 175 aa), ATXN1Q30 (818 aa), ATXN1Q82 (868 aa),
ATXN1Q30NT (458 aa), ATXN1Q82NT (508 aa), ATXN3Q25
(360 aa) and ATXN3Q73 (408 aa) were PCR amplified with
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Pwo SuperYield DNA polymerase (Roche) from the plasmids
pOTB7-MED15 (cloneID:CCSB7005), pAS2-1-ATAXIN1Q30,
pAS2-1-ATAXIN1Q82, pBTM116-ATXN3Q25 and pBTM116-
ATXN3Q73 and cloned into the Gateway plasmid pDONR221
(Invitrogen). Oligonucleotides (MED15CC-forward, MED15CC-
reverse, ATXN1-forward, ATXN1-reverse-FR, ATXN1-reverse-
FL, ATXN3-forward, and ATXN3-reverse, Table S6) were
purchased from BioTez Berlin-Buch GmbH, Germany. PCR
reactions (50 ml volume) contained 50 ng plasmid DNA, 100 pmol
primer oligonucleotides, 2 mMMgCl2, 50 mMKCl, 10 mM Tris–
HCl pH 8.0, 0.1% Triton-X100 and 2.5 U Pwo DNA polymerase.
Fragments were amplified in 30 cycles with the following profile:
45 s denaturation at 93uC, 45 s annealing at 52uC and 3 min
extension at 72uC. Amplified 589 bp DNA fragments were isolated
from agarose gels and combined with the pDONR221 plasmid
(Invitrogen) at a 1:2 ratio in the presence of BP clonase (Invitrogen).
After incubation for 16 h at 25uC the resulting entry DNA plasmids
were transformed into competent Mach1 E. coli cells (Invitrogen). E.
coli clones were selected on LB agar plates supplemented with
Kanamycin and analyzed by BsrGI restriction digestion (NEB).
Finally, the identity of DNA fragments was verified by DNA
sequencing. The pJET-MED15CC plasmid was generated by
isolating the 554 bp PCR product from an agarose gel and blunt
end cloning into the pJET1.2 vector (Fermentas) according to the
manufacturer’s recommendations. Identity of the DNA fragment
was verified by DNA sequencing. To create the Gateway
compatible entry plasmid encoding Pum1-MED15CC (pePUM1-
MED15CC), the 537 bp cDNA fragment MED15CC was
subcloned into the unique AatII site in the Gateway compatible
plasmid pOBT7-Pum1 (cloneID:CCSB6127) encoding the Pum1
protein (Figure 6A). The correct insertion of the cDNA fragment
was confirmed by restriction digestion. To create the Gateway
compatible entry plasmid (pe-MED15DCC) encoding MED-
15DCC, the plasmid sequence of pOTB7-MED15 (cloneID:
CCSB7005) was amplified by PCR without the insert encoding
the N-terminal MED15CC domain (A96-P314) using MED-
15DCC_Fwd and MED15DCC_Rev primers (Table S6). For
amplification of the linear plasmid DNA we used the Phusion
Site-Directed Mutagenesis Kit (Finnzymes) following the recom-
mended protocol. The resulting MED15DCC cDNA was verified
by DNA sequencing.
Generation of expression plasmids
For cell-based modifier screens, we cloned 202 computationally
selected genes (Table S7) into the plasmids pFLAG-GW and
pACT4-DM (Invitrogen), respectively. The cDNA fragment
encoding ATXN1Q82NT was cloned into the pdEYFP-C1Amp
vector (Imagenes). cDNA fragments encoding ATXN1Q30 and
ATXN1Q82 were cloned into the vector pPA-Reni-DM [45] for
LUMIER interaction assays. cDNAs encoding Pum1, MED15
and U2AF2 were also subcloned into the plasmid pFire-V5-DM
[45]. Mammalian expression plasmids were generated by sub-
cloning of cDNAs encoding the proteins MED15, MED15DCC,
Pum1, Pum1-MED15CC, MED15CC, STUB1 and S100B into
the plasmids pmCherryGW (Invitrogen) and pFLAG-GW (Invi-
trogen). To produce proteins in E. coli, the cDNA fragments
encoding ATXN1Q82 and MED15CC were cloned into the
expression vector pGEX-6P-1 (Amersham Biosciences); cDNA
fragments encoding the proteins MED15 and Pum1 were
subcloned into the plasmid pDESTCo (Invitrogen). For generation
of destination plasmids the Gateway recombination cloning
technology was applied as recommended by the manufacturer
(Invitrogen). Entry plasmids and empty destination vectors (Table
S8) were combined in a 1:3 ratio in the presence of LR clonase
(Invitrogen) and subsequently incubated for 1 h at 25uC. Then,
plasmids were transformed into competent Mach1 E. coli cells
(Invitrogen) as recommended by the manufacturer. Finally,
plasmid DNAs were purified from E. coli clones using the QIAprep
96 Turbo Miniprep Kit (Qiagen) and analyzed by BsrGI (NEB)
restriction digestion.
Overproduction of recombinant proteins in COS-1 cells
COS-1 cells were grown to 70–80% confluency in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 5% fetal calf
serum, penicillin (100 mg/ml) and streptomycin (100 mg/ml). For
cDNA overexpression experiments, cells at passage 5–6 were
seeded into 96-well cell culture plates (12,000 cells/well). Then,
they were co-transfected with pdEYFP-C1Amp (0.4 mg) and a
pFLAG-GW-based plasmid (0.4 mg) encoding e.g., the proteins
YFP-ATXN1Q82NT and the FLAG-tagged modifier protein
MED15. Transfections were performed using Lipofectamine
2,000 in Opti-MEM (Invitrogen). In each co-transfection exper-
iment ,200 putative modifiers were systematically tested. All co-
transfection experiments were performed in triplicates. Transfect-
ed COS-1 cells were harvested after 48 h and lysed in 1% NP-40
PBS, supplemented with a complete protease inhibitor cocktail
mix (Sigma). To separate the supernatant from the insoluble pellet,
crude cell extracts were centrifuged at 30,000 rpm for 30 min.
The pellet was dissolved in 8 M urea.
Antibodies
To generate a polyclonal antibody against ATXN1, two
peptides (aa11–26, CLPPKKREIPATSRSS and aa326–338,
GEMEKSRRYGAPS) were independently fused to the carrier
Keyhole Limpet Hemocyanin (KLH) protein and injected into
rabbits using standard immunization procedures (Eurogentec,
Belgium). The resulting immune sera were affinity purified against
His-tagged ATXN1Q30 immobilized on a Ni-NTA column
(Qiagen), according to manufacturer’s instructions. The specificity
of antibodies was confirmed by SDS-PAGE and immunoblotting
using protein extracts from transiently transfected COS-1 cells
(Figure S14). The anti-ATXN1 antibody SA4645 was used for the
detection of full-length ATXN1 and ATXN1Q82NT. The mouse
monoclonal anti-FLAG antibody M2 (Sigma-Aldrich) was used
(1:1,000) for the detection of FLAG-tagged modifier proteins
produced in COS-1 cells. Recombinant ATXN3Q25 and
ATXN3Q73 proteins were detected with the anti-MJD CT
antibody (1:1,000) [83]. To monitor mCherry-tagged recombinant
fusion proteins, Living Colors mCherry monoclonal antibody
(1:1,000, Clontech) was used.
siRNA knock down of target genes in COS-1 cells
For siRNA assays, COS-1 cells were transfected with 0.2 mg
of a pdEYFP-C1Amp vector encoding YFP-ATXN1Q82NT
and 2 pmol target gene siRNA in 24 well plates (50,000 cells
per well). siRNAs were obtained from the HP GenomeWide
siRNA library (Qiagen). The cell culture conditions and
transfection reagents were as described in protein overproduc-
tion experiments. To confirm the knock-down of target genes
qRT-PCR experiments were performed. RNA was purified
from cells using the RNeasy Mini Kit (Qiagen) as recom-
mended by the manufacturer. cDNA generation and qRT-
PCR reactions were performed using the Dynamo FLASH
SYBR Green qPCR kit (Finnzymes) in an Applied Biosystems
7,500 operating system. Each experiment was performed in
triplicate. The sequences of oligonucleotides used in qPCR
experiments are displayed in Table S9.
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Caspase 3/7 toxicity assays
An equal number of COS-1 cells (12,000 cells per well) were co-
transfected with plasmids encoding YFP-ATXN1Q82NT and a
potential FLAG-tagged modifier protein. Caspase 3/7 activity in
transfected COS-1 cells was measured using the Apo-ONE
Homogeneous Caspase-3/7 Assay kit (Promega). Briefly, cell lysis
buffer was mixed with a pre-fluorescent caspase 3/7 substrate and
added to COS-1 cells 48 h after transfection. The pre-fluorescent
caspase 3/7 substrate was cleaved by activated caspase 3/7 and
resulted in the formation of a fluorescent product. Fluorescence
was measured in a plate reader (TECAN Infinite M200) and
caspase 3/7 activity was normalized to the cell numbers quantified
via high content imaging microscopy (Thermo Scientific, Arrays-
can VTI). Each experiment was performed in triplicates.
Filter retardation assays
For quantification of insoluble polyQ-containing protein aggre-
gates a filter retardation assay was applied [32]. COS-1 cells were
transfected as described in the previous paragraph. Equal amounts
of crude cell extracts (120 mg total protein) were mixed with an
equal volume of 4% SDS and 100 mM DTT and heated at 95uC
for 5 min. Samples were diluted in 100 ml 0.2% SDS and filtered
through a 0.2 mm cellulose acetate membrane. SDS-resistant
aggregates retained on the membrane were detected using the
polyclonal anti-ATXN1 antibody SA4645 (1:1,000).
Quantification of insoluble polyQ-containing protein
aggregates by high-content fluorescence imaging
SH-EP cells were grown at 37uC and 5% CO2 in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 4.5 g/l D-
glucose, 10% fetal calf serum, penicillin (100 mg/ml) and streptomycin
(100 mg/ml). Cells were seeded in 96-well cell culture plates (10,000
cells/well) and co-transfected with a 1:1 mix of cDNAs encoding YFP-
ATXN1Q82 or YFP-ATXN1Q82NT and mCherry-tagged modifiers
(200 ng each). 48 h after transfection cells were fixed with 4%
paraformaldehyde (Sigma) and DNAwas stained with Hoechst 33342
(1:2,500) (Invitrogen). The cell culture plates were then placed into a
high-content screening (HCS) cell analysis system (Arrayscan VTI,
Thermo Scientific). The principle of HCS analysis is described
elsewhere [84]. Nuclei were identified by Hoechst fluorescence; cell
dimensions were fitted using the ArrayScan VTI software (Thermo
Scientific). ATXN1Q82, ATXN1Q82NT and ATXN3 overproduc-
tion was quantified by YFP fluorescence and modifiers were
monitored by mCherry fluorescence. The fluorescence signals were
normalized to cell numbers. Experiments were performed in triplicate.
Confocal microscopy of YFP-ATXN1Q82 and -
ATXN1Q82NT aggregates and modifier proteins in COS-1
cells
COS-1 cells were grown at 37uC and 5% CO2 in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 4.5 g/l D-
glucose, 10% fetal calf serum, penicillin (100 mg/ml) and strepto-
mycin (100 mg/ml). Cells were seeded on coverslips in 24-well cell
culture plates (25,000 cells/well). Co-transfections were performed
using cDNAs encoding YFP-ATXN1Q82, YFP-ATXN1Q82NT
and mCherry-tagged modifiers (500 ng each). For single transfec-
tions cells were transfected with cDNAs encoding YFP-
ATXN1Q30, YFP-ATXN1Q82, YFP-ATXN1Q30NT or YFP-
ATXN1Q82NT (500 ng each). 48 h after transfection cells were
fixed with 4% paraformaldehyde (Sigma), stained with Hoechst
33342 (1:2,500 in PBS, Invitrogen) and mounted using ProLong
Gold antifade reagent (Invitrogen). ATXN1Q82 and
ATXN1Q82NT overproduction was monitored by YFP fluores-
cence and modifiers were detected by mCherry fluorescence.
Images were recorded using a Leica SP2 confocal microscope.
Knock-down of target genes in SCA1 transgenic flies
For knock-down of niki and MED15 gene expression the VDRC
stocks 16,120 and 21,809 were used (http://stockcenter.vdrc.at/
control/main). UAS-GFP and UAS-GFP-RNAi lines, provided by
C. Antoniewski were used as controls. J. Botas and M. O.
Fauvarque kindly provided the fly lines harbouring UAS-
ATXN1Q82 and GMR-GAL4 genes. Initially, a stable UAS-
ATXN1Q82;GMR-GAL4 line was generated. To analyze the
effects of niki and MED15 target gene knock-downs on
ATXN1Q82 induced eye degeneration UAS-ATXN1Q82;GMR-
GAL4 females were crossed with males of niki and MED15 RNAi
lines and with males of UAS-GFP and UAS-GFP-RNAi control
lines, respectively. The eye structure of male progeny (n.20) was
examined using Leica and Zeiss stereomicroscopes. For electron
microscopy imaging, flies (n.5) were desiccated at 40uC overnight,
dried by the critical point method with liquid N2, sputter-coated
with gold and visualized with a scanning electron microscope (JEOL
JSM 840-A).
Detection of protein–protein interactions
For LUMIER assays protein A (PA)-Renilla luciferase (RL)-
tagged ATXN1 fusion proteins (PA-RL-ATXN1Q30 or PA-RL-
ATXN1Q82) were co-produced with firefly luciferase-tagged
modulator proteins FL-Pum1, FL-MED15 or FL-U2AF2 in
HEK293 cells. After 48 h protein complexes were co-immuno-
precipitated from cell extracts with IgG coated magnetic beads
(Dynabeads; Invitrogen); interactions between bait (PA-RL
fusions) and prey proteins (FL fusions) were monitored by
quantification of firefly luciferase activities [45]. Quantification
of Renilla luciferase activity was used to confirm that PA-RL-
tagged bait proteins are successfully immunoprecipitated from
cell extracts. To detect Renilla and firefly luciferase based
luminescence in samples the Dual-Glo Luciferase Kit (Promega)
was used. Bioluminescence was quantified in a luminescence
plate reader (TECAN Infinite M1000). A representative
example of a typical LUMIER-based co-immunoprecipitation
experiment with transiently transfected HEK293 cells is shown
schematically in Figure 4A and Figure S8. It is important to
note that for each protein pair that was investigated (interaction
between selected bait and prey proteins) three co-immunopre-
cipitation experiments (Co-IPs A–C) were performed in parallel
in HEK293 cells, in order to assess the specificity of an
interaction. For example, to investigate the interaction between
the proteins ATXN1Q30 and Pum1 the protein pairs (A) PA-
RL-ATXN1Q30/FL-Pum1, (B) PA-RL/FL-Pum1 and (C) PA-
RL-ATXN1Q30/FL are individually co-produced in HEK293
cells (Figure S8). The proteins PA-RL and FL in experiments B
and C are used as controls to examine background protein
binding. The resulting protein complexes in Co-IPs A–C are
systematically analyzed by quantification of firefly luciferase
activity. By dividing the firefly luminescence activity measured
in sample A through activities found in samples B and C the R-
op and R-ob binding ratios are obtained, which function as a
measure for the protein interaction specificity. Low R-op values
indicate unspecific prey protein interactions, while low R-ob
values indicate unspecific bait protein interactions (Figure S8).
Based on empirical studies with a set of well-characterized
positive and negative interaction pairs (not shown), we defined
that R-op and R-ob binding ratios of .1.5 are indicative of
reliable protein-protein interactions.
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Protein purification and aggregation assays
For the production of GST- and His-tagged fusion proteins the
genes encoding the proteins ATXN1Q82, MED15CC, MED15
and Pum1 were cloned into the vectors pGEX-6P-1 and pDEST-
Co and the resulting plasmids pGEX-6P-1-ATXN1Q82, pGEX-
6P-1-MED15CC, pDEST-Co-MED15 and pDEST-Co-Pum1
were transformed into E. coli BL21 cells. Recombinant proteins
were purified using glutathione agarose (Sigma) or Ni-NTA
agarose (Qiagen) beads according to the instructions of manufac-
turers. His-tagged Pum1 protein was purified under denaturing
conditions using 6 M guanidium-HCl and refolded in buffer A
(500 mM (NH4)2SO4, 50 mM MgCl2, 10 mM DTT, 30%
glycerol) for 16 h on ice. The supernatant was dialyzed against
buffer B (10 mM Tris-Cl pH 8, 100 mM NaCl, 1 mM EDTA,
10% glycerol) for 16 h at 4uC. His-Pum1 protein was then
concentrated using mini spin-columns (Millipore).
For in vitro aggregation assays, GST-ATXN1Q82 (5–7 mM) was
incubated with His-tagged MED15, His-tagged Pum1 or GST-
tagged MED15CC in the presence of PreScission Protease
(Amersham Pharmacia) at 30uC with constant shaking
(300 rpm). Reactions were stopped by freezing of samples in
liquid nitrogen. 25 mg of GST-ATXN1Q82 was filtered through a
0.2 mm cellulose acetate membrane and protein aggregates
retained on filter membranes were detected using the polyclonal
anti-ATXN1 antibody SA4645 (1:1,000).
Circular dichroism spectroscopy
GST and GST-MED15CC proteins were dialyzed in 50 mM
Na2HPO4/NaH2PO4, 150 mM NaF pH 7.5 for 16 h at 4uC. Far-
UV circular dichroism spectra of GST and GST-MED15CC
(5 mM) were recorded at 20uC using a Chirascan CD spectrometer
(Applied Biophysics) at a bandwidth of 1 nm. Spectra were
collected at 1 nm intervals from 250 to 190 nm and at least 3
average values for each measurement were smoothed and
normalized to mean residual weight ellipticity [h] using the Pro-
Data software (Applied Biophysics). MED15CC CD values were
acquired by substraction of the GST CD spectrum from the GST-
MED15CC CD spectrum. Prediction of secondary protein
structure based on the CD data was performed using the K2D2
program [49].
Bioinformatics analysis
The EASE program [34] was used to identify over-represented
functional categories (Gene Ontology annotation and KEGG
pathways) among the identified 21 YFP-ATXN1Q82NT toxicity
modifiers. The modifier genes were compared to the human
genome; a Fisher’s exact test was performed to identify over-
represented functional categories. We only considered categories
with adjusted p-values,0.05 (adjusted with the Bonferroni
method) as statistically significant. For the prediction of coiled-
coil domains (CC) in amino acid sequences of modifier proteins
the COILS program was used [41]. Only high probability CC
sequences (0.8–1) were considered for further investigations. We
used Chi-square tests to compare the number of YFP-
ATXN1Q82NT toxicity modifiers with CC domains to the human
proteome (73,427 protein sequences in SwissProt DB, 20.3%).
To identify glutamine-rich (Q-rich) or polyglutamine (polyQ)
proteins, a window of 50 amino acids was passed over each protein
sequence. For each window position the fraction of Qs amongst all
residues or the number of consecutive Qs was counted. A protein
was considered as Q-rich when it contains .50% Qs in a stretch
of at least 10 amino acids; in comparison a protein was defined as
a polyQ protein when it contains a stretch of .10 consecutive Qs.
Sequence homologues of human Pum1 and MED15 were
selected using the NCBI BLAST sequence search program [28]. For
multiple sequence alignments we used the EBI’s MUSCLE web tool
[85]. The local glutamine composition of aligned sequences was
determined by shifting a window of 50 amino acids over all
sequences and by counting the fraction of Qs amongst all residues
for each window position (not considering gaps). Additionally, the
fraction of Qs in an uninterrupted polyQ stretch (.5) was counted
for each protein. This information was used to compare the Q and
polyQ content of homologous proteins.
Supporting Information
Figure S1 Western blot analysis of FLAG-tagged modulator
proteins. Plasmids encoding FLAG-tagged modifier proteins were
randomly selected and transfected into COS-1 cells. Protein
extracts were prepared after 48 h and analyzed by SDS-PAGE
and immunoblotting using the anti-FLAG antibody M2. The same
amount of total protein was loaded in each lane.
(TIF)
Figure S2 Detection and quantification of YFP-ATXN1Q30NT
or YFP-ATXN1Q82NT aggregates in COS-1 cells. (A) A
schematic representation of full-length and truncated ATXN1
proteins with pathogenic and non-pathogenic polyQ tracts. (B)
Confocal microscopy pictures of YFP-ATXN1Q82NT and YFP-
ATXN1Q30NT protein aggregates detected in COS-1 cells. Cells
were analyzed after 48 h. Nuclei are stained with Hoechst 33342
(blue) and YFP-ATXN1Q82NT and YFP-ATXN1Q30NT protein
deposits are shown in green. (C) Quantification of YFP-
ATXN1Q30NT and YFP-ATXN1Q82NT aggregates in COS-1
cells using a high-content screening cell analysis system (Arrayscan
VTI, Thermo Scientific).
(TIF)
Figure S3 Schematic overview of modifier cytotoxicity screening
strategy. COS-1 cells were co-transfected with pairs of plasmids
encoding YFP-ATXN1Q82NT and a potential toxicity modifier.
Human proteins that either enhance (green) or suppress (red) the
toxicity of pathogenic YFP-ATXN1Q82NT are identified in a cell-
based screen and subsequently retested in cells in the absence
YFP-ATXN1Q82NT fusion protein. Modulators were only con-
sidered for further investigations when they specifically influence
YFP-ATXN1Q82NT cytotoxicity in cell-based assays.
(TIF)
Figure S4 Western blot analysis confirms the production of
YFP-ATXNQ82NT toxicity modifiers in COS-1 cells. Overpro-
duction of ATXN1Q82NT cytotoxicity modifiers in transiently
transfected COS-1 cells was analyzed after 48 h by SDS-PAGE
and immunoblotting using the anti-FLAG antibody M2. Asterisks
indicate modifier proteins.
(TIF)
Figure S5 Effects of human proteins on pathogenic ATXN3
cytotoxicity and aggregation. (A) Relative caspase 3/7 activity
change induced by overproduction of proteins YFP-ATXN3Q25
or YFP-ATXN3Q73 in COS-1 cells compared to YFP overpro-
ducing cells. Caspase 3/7 activity was significantly increased in
cells producing the ATXN3 fusion protein with a pathogenic
polyQ tract compared to the wild-type protein (Student’s t-test, **
p,0.01, n= 3). Error bars indicate SD. (B) Detection of SDS
insoluble protein aggregates by filter retardation assay. The YFP-
ATXN3Q73 fusion protein forms SDS-insoluble protein aggre-
gates. Equal amounts of total protein were loaded. (C) Effects of
modifier proteins on YFP-ATXN3Q73 cytotoxicity; 21 previously
identified YFP-ATXN1Q82NT toxicity modifiers (Figure 1E) were
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systematically tested in cell-based assays. We found that only the
proteins P0 (RPLP0), Vps4B (VPS4B), Ran (RAN) and Nek8
(NEK8) influence YFP-ATXN3Q73 toxicity. (D) Effects of
modifier proteins on YFP-ATXN3Q73 aggregation; overproduc-
tion of Ran and Vps4B enhanced YFP-ATXN3Q73 aggregation.
(TIF)
Figure S6 siRNA treatment reduces the expression of modifier
genes in mammalian cells. siRNA treated COS-1 cells were
analyzed by qRT-PCR. siRNA knock-down of six randomly
selected target genes caused a reduction of mRNA levels by 50–
90% in comparison to the non-targeting control. mRNA levels
were normalized to the mRNA levels of b-actin. Data is shown as
mean 6 SD for three independent experiments performed in
triplicates.
(TIF)
Figure S7 Prediction of coiled-coil domains in related MED15
and Pum1 proteins. Coiled-coil domains in proteins were
predicted using the COILS program with a window size of 28
amino acids. (A) Predicted CC domain of human MED15 and its
orthologues. (B) Predicted CC domain of human Pum1 and its
orthologues. Abbreviations: hs, Homo sapiens; mm, Mus musculus;
dm, Drosophila melanogaster; ce, Caenorhabditis elegans.
(TIF)
Figure S8 Schematic representation of a cell-based LUMIER co-
immunoprecipitation assay. To investigate the interaction between
the proteins ATXN1Q30 (bait) and Pum1 (prey) the fusion protein
pairs (A) PA-RL-ATXN1Q30/FL-Pum1, (B) PA-RL/FL-Pum1
and (C) PA-RL-ATXN1Q30/FL were co-produced in HEK293
cells. After 48 h the cells were lysed and protein extracts were
applied to IgG coated magnetic beads (Dynabeads; Invitrogen) for
co-immunoprecipitation (co-IP) of interacting proteins. Following
the co-IP the firefly luminescence signal was determined for all three
samples (A–C) using a luminescence plate reader. In sample A,
as a result of the interaction between PA-RL-ATXN1Q30 and
FL-Pum1 a high luminescence signal was detected. In comparison,
relatively low signals were obtained in control samples B and C.
Using the measured values we calculated the binding ratios R-op
and R-ob, which are measure for the specificity of the ATXN1Q30
and Pum1 interaction. Based on previous empirical studies with
well-characterized interaction test pairs, we define an interaction as
positive when the calculated R-op and R-ob ratios are .1.5.
(TIF)
Figure S9 Detection of firefly luciferase and Renilla luciferase
tagged fusion proteins in HEK293 cell extracts. Production of
Renilla and firefly luciferase-tagged fusion proteins in HEK293
cells was monitored by quantification of luminescence activity of
protein extracts. Data are shown as mean 6 SD for three separate
experiments performed in triplicates. Abbreviations: FL - firefly
luciferase; RL - Renilla luciferase; PA - protein A; RLU - relative
light units.
(TIF)
Figure S10 Purification of recombinant GST- and His-tagged
fusion proteins for cell-free aggregation assays. (A) Schematic
representation of a spontaneous ATXN1Q82 aggregation reaction
in the presence of a modifier protein. Aggregation of ATXN1Q82
is initiated by proteolytic cleavage of the fusion protein GST-
ATXN1Q82 with PreScission protease. Insoluble ATXN1Q82
aggregates form spontaneously over time and are quantified by
filter retardation assay. The effects of modifiers can be assessed in
a time and concentration dependent manner. (B) GST- and His-
tagged fusion proteins were produced in E. coli and purified by
affinity chromatography. Analysis by SDS-PAGE and Coomassie
staining confirmed that recombinant fusion proteins with expected
sizes are produced in E. coli.
(TIF)
Figure S11 The recombinant proteins His-MED15 and His-
Pum1 influence spontaneous ATXN1Q82 aggregation in a
concentration-dependent manner. (A) Detection of SDS-insoluble
ATXN1Q82 aggregates by filter retardation assay. GST-
ATXN1Q82 (5 mM) was incubated with PreScission protease
and modulator proteins (2.5, 5 or 10 mM) and formation of
insoluble ATXN1Q82 protein aggregates was quantified after
48 h by filter assay. His-MED15 in a concentration dependent
manner increased spontaneous ATXN1Q82 aggregation, while
His-Pum1 has the opposite effect. SDS-insoluble ATXN1Q82
protein aggregates retained on filter membranes were detected
using the anti-ATXN1 antibody SA4645. (B) Quantification of
filter retardation assay data with the AIDA densitometry software.
Error bars represent SD of three independent experiments.
(TIF)
Figure S12 Effects of modulator proteins on aggregation of full-
length YFP- ATXN1Q82. (A) Effects of mCherry-tagged proteins
Pum1-MED15CC, Pum1, MED15, S100B, STUB1 and luciferase
on spontaneous YFP-ATXN1Q82 aggregation in human neuro-
blastoma SH-EP cells. The formation of polyQ-containing
ATXN1 aggregates was quantified by fluorescence imaging after
48 h. We found that the hybrid protein Pum1-MED15CC in
comparison to the wild-type Pum1 and the luciferase control
protein (100%) readily promotes YFP-ATXN1Q82 aggregation,
confirming the results obtained with the YFP-ATXN1Q82NT
protein (Figure 6B). An increase of YFP-ATXN1Q82 aggregates
was also observed in MED15 and STUB1 overproducing SH-EP
cells. In strong contrast, a suppression of spontaneous YFP-
ATXN1Q82 aggregation was detected with the control protein
S100B. Data are shown as mean 6 SD from three independent
experiments. Experiments were performed in triplicates. Student’s
t-test was used for statistical comparisons, p,0.05. (B) Analysis of
spontaneous YFP-ATXN1Q30 and YFP-ATXN1Q82 aggrega-
tion in COS-1 cells by confocal microscopy. COS-1 cells were
transfected with plasmids encoding the full-length ATXN1
proteins YFP-ATXN1Q30 and YFP-ATXN1Q82 and after 48 h
cells were investigated by confocal microscopy. Nuclei were
stained with Hoechst (blue). We found that both wild-type and
mutant ATXN1 fusion proteins form nuclear inclusions in COS-1
cells (green). (C) Quantification of aggregate number and size in
YFP-ATXN1Q30 and YFP-ATXN1Q82 overproducing cells a
high-content screening cell analysis system (Arrayscan VTI,
Thermo Scientific). (D) Detection of YFP-ATXN1Q30 and
YFP-ATXN1Q82 fusion proteins in COS-1 cell extracts by
SDS-PAGE and immunoblotting. Proteins were detected using
anti-GFP and anti-actin antibodies. Abbreviations: TL - total
lysate; P – pellet; Sup – supernatant.
(TIF)
Figure S13 Production of mCherry- and FLAG-tagged modifier
proteins in mammalian cells. SH-EP neuroblastoma cells were
transfected with plasmids encoding (A) mCherry- or (B) FLAG-
tagged modifier proteins; protein extracts were analyzed after 48 h
by SDS-PAGE and immunoblotting. Recombinant proteins with
the expected sizes were detected with an anti-mCherry (A) or an
anti-FLAG antibody (B). The endogenous protein actin was used
as a loading control.
(TIF)
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Figure S14 The SA4645 antibody specifically recognizes YFP-
tagged ATXN1 fusion proteins in crude cell extracts. COS-1 cells
were transiently transfected with plasmids encoding YFP-tagged
ATXN1Q30, ATXN1Q82, ATXN1Q30NT, ATXN1Q82NT,
ATXN3Q25 or ATXN3Q73 fusion proteins and cell extracts
were analyzed by SDS-PAGE and immunoblotting using the anti-
ATXN1 antibody SA4645. We observed that all YFP-tagged
ATXN1 and ATXN3 fusion proteins were detected with an anti-
GFP antibody (A). In contrast, the SA4645 antibody detects
ATXN1 but not ATXN3 fusion proteins in cell extracts (B),
indicating that the antibody is specific for ATXN1. An anti-actin
antibody was utilized to detect endogenous actin in cell extracts
(loading control). Abbreviations: IB – immunoblot; a-GFP – anti-
GFP antibody; a-ATXN1 - anti-ATXN1 antibody SA4645.
(TIF)
Table S1 List of human genes encoding potential ATXN1 toxicity
and aggregation modifiers. Genes encoding putative modifier
proteins were predicted using the available literature information
from modulator studies in lower model organisms. In addition,
interaction partners of polyQ-containing disease proteins (ATXN1,
ATXN2, ATXN3 and ATXN7) were selected as potential
modulator proteins.
(XLS)
Table S2 Human genes encoding YFP-ATXN1Q82NT toxicity or
aggregation modulators. The genes encoding YFP-ATXN1Q82NT
toxicity modulators were initially identified in cDNA overexpression
experiments in COS-1 cells. In further studies their effects on YFP-
ATXN1Q82NT aggregation was investigated. Finally, we examined
whether identified YFP-ATXN1Q82NT toxicity modulators also
influence YFP-ATXN3Q73 toxicity and aggregation in COS-1 cells.
(XLS)
Table S3 Selected genes for siRNA knock-down experiments in
cell-based assays. 15 genes encoding potential ATXN1Q82NT
toxicity modifiers were investigated in cell-based siRNA knock-
down experiments.
(XLS)
Table S4 Literature-based annotation of potential cellular
functions of ATXN1Q82NT toxicity modifiers. ATXN1Q82NT
toxicity modifiers were categorized using the available literature
information retrieved from PubMed.
(XLS)
Table S5 Predicting coiled-coil domains in ATXN1Q82NT
toxicity modifiers. Coiled-coil (CC) domains in modifier proteins
were predicted using the COILS program and a window size of 28
amino acids.
(XLS)
Table S6 Oligonucleotides for PCR amplification of cDNA
fragments. PCR amplified cDNA fragments were utilized for
constructing Gateway compatible entry plasmids. We gene-
rated cDNA fragments for the proteins MED15CC, MED15DCC,
ATXN3Q25, ATXN3Q73, ATXN1Q30, ATXN1Q82,
ATXN1Q30NT and ATXN1Q82NT.
(XLS)
Table S7 List of cDNA entry clones for construction of
destination plasmids.
(XLS)
Table S8 List of destination plasmids for expression of cDNAs in
E. coli and mammalian cells.
(XLS)
Table S9 List of oligonucleotides for qPCR experiments.
(XLS)
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